Skip to Main Content

Paper Details

Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration.
RMD Open
26
2020
Ankylosing Spondylitis Disease, Secukinumab, Spondyloarthritis, axSpA, axial spondyloarthritis, b/tsDMARD, b/tsDMARDs, bionave, patients, secukinumab
Author NameAffiliation
Jakub Z??vadaInstitute of Rheumatology
Irene E van der Horst-BruinsmaAmsterdam University Medical Centres, VU University Medical Centre
  • 1 - 2

Datasets

Release 1.2